MX366090B - Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2. - Google Patents

Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.

Info

Publication number
MX366090B
MX366090B MX2013013200A MX2013013200A MX366090B MX 366090 B MX366090 B MX 366090B MX 2013013200 A MX2013013200 A MX 2013013200A MX 2013013200 A MX2013013200 A MX 2013013200A MX 366090 B MX366090 B MX 366090B
Authority
MX
Mexico
Prior art keywords
patients
diabetes type
pharmaceutical combination
weight loss
weight gain
Prior art date
Application number
MX2013013200A
Other languages
English (en)
Other versions
MX2013013200A (es
Inventor
Boka Gabor
Silvestre Louise
Miossec Patrick
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MX2013013200A publication Critical patent/MX2013013200A/es
Publication of MX366090B publication Critical patent/MX366090B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere al uso de una cantidad terapéuticamente efectiva de la combinación farmacéutica que comprende (a) desPro36Exendina-4(1-39)-Lys6-NH2 y/o una sal farmacéuticamente aceptable de la misma, y (b) metformina y/o una sal farmacéuticamente aceptable de la misma, en la preparación de un medicamento para mejorar el control glucémico en un paciente que padece diabetes de tipo 2 que lo necesita, en donde el paciente que ha de tratarse es menor de 50 años y tiene una concentración de glucosa en plasma postprandial de 2 horas de por lo menos 14 mmol/L, y en donde el paciente que ha de tratarse tiene un valor HbA1C de por lo menos 8%, y en donde el diabetes de tipo 2 que ha de tratarse no está adecuadamente controlada con sólo metformina, en donde el paciente es obeso.
MX2013013200A 2011-05-13 2012-05-11 Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2. MX366090B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11166058 2011-05-13
PCT/EP2012/058745 WO2012156296A1 (en) 2011-05-13 2012-05-11 Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients

Publications (2)

Publication Number Publication Date
MX2013013200A MX2013013200A (es) 2014-10-24
MX366090B true MX366090B (es) 2019-06-27

Family

ID=46146838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013200A MX366090B (es) 2011-05-13 2012-05-11 Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.

Country Status (11)

Country Link
US (1) US8735349B2 (es)
EP (1) EP2707016A1 (es)
JP (1) JP6121403B2 (es)
KR (1) KR20140043756A (es)
CN (2) CN107496907A (es)
AU (1) AU2012257847B2 (es)
BR (1) BR112013029269A8 (es)
CA (1) CA2835496C (es)
MX (1) MX366090B (es)
RU (2) RU2761624C2 (es)
WO (1) WO2012156296A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
EP3202394A1 (de) 2009-07-06 2017-08-09 Sanofi-Aventis Deutschland GmbH Wässrige insulinzubereitungen enthaltend methionin
PE20121316A1 (es) 2009-11-13 2012-10-05 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1 y metionina
PT2554183T (pt) 2009-11-13 2018-07-09 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
TWI397617B (zh) 2010-02-12 2013-06-01 Masahiro Hoshino Metal silicon purification device
US20140148384A1 (en) 2010-08-30 2014-05-29 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
EP2670427A1 (en) * 2011-02-02 2013-12-11 Sanofi-Aventis Deutschland GmbH Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) * 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
KR20160104724A (ko) 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 약제학적 제형
CN105899191B (zh) 2014-01-09 2020-06-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
RU2016132340A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулина аспарта
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) * 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
WO2002067868A2 (en) 2001-02-26 2002-09-06 Millennium Pharmaceuticals, Inc. Methods for the treatment of metabolic disorders, including obesity and diabetes
BR0314799A (pt) 2002-09-27 2005-07-26 Market Biosciences Corp Controle glicêmico aperfeiçoado para pré-diabetes e/ou diabetes do tipo ii usando ácido docosahexaenóico
ITRM20030053A1 (it) * 2003-02-10 2004-08-11 Sigma Tau Ind Farmaceuti Associazione di farmaci antidiabetici.
CN101130090B (zh) * 2006-08-22 2010-05-12 复旦大学 Brsk2在制备抗糖尿病药物中的应用
CL2008000133A1 (es) * 2007-01-19 2008-05-23 Boehringer Ingelheim Int Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e
WO2008111956A2 (en) * 2007-03-09 2008-09-18 Symcopeia Company Fatty acid oxidation inhibitors treating hyperglycemia and related disorders
AU2009238272B2 (en) * 2009-11-13 2014-05-08 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
HUE026489T2 (en) 2009-11-13 2016-06-28 Sanofi Aventis Deutschland Combination of lixisenatide and metformin to treat type 2 diabetes

Also Published As

Publication number Publication date
CA2835496A1 (en) 2012-11-22
US20130023467A1 (en) 2013-01-24
CA2835496C (en) 2022-06-07
MX2013013200A (es) 2014-10-24
CN103648520A (zh) 2014-03-19
RU2017143385A3 (es) 2021-03-04
RU2017143385A (ru) 2019-02-14
WO2012156296A8 (en) 2013-02-21
BR112013029269A2 (pt) 2016-11-29
CN107496907A (zh) 2017-12-22
RU2761624C2 (ru) 2021-12-13
WO2012156296A1 (en) 2012-11-22
AU2012257847B2 (en) 2017-05-25
JP2014514355A (ja) 2014-06-19
US8735349B2 (en) 2014-05-27
BR112013029269A8 (pt) 2018-01-16
KR20140043756A (ko) 2014-04-10
JP6121403B2 (ja) 2017-04-26
EP2707016A1 (en) 2014-03-19
RU2013155473A (ru) 2015-06-20

Similar Documents

Publication Publication Date Title
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
SI2739615T1 (sl) Fenil-3-aza-biciklo(3.1.0)heks-3-il-metanoni in njihova uporaba kot zdravilo
MX2014002159A (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
IL232251B (en) Pharmaceutical combination for use in the treatment of type 2 diabetes patients
CA2865972C (en) Inhalable dry powders
ZA201405436B (en) Herbicide tolerant cotton event pdab4468.19.10.3
JO3343B1 (ar) أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها
EP3736282C0 (en) CELL-PERFORMING PEPTIDE, CONJUGATE THEREOF AND COMPOSITION WITH THE CONJUGATE
SG10201901922VA (en) Compositions and methods for treating metabolic disorders
AU346731S (en) 1. Chair without arms 2. chair with arms
EA033171B1 (ru) Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол
GB2497453B8 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
WO2012106427A3 (en) Methods for treating diabetic foot ulcers
WO2012024634A3 (en) Environmentally-responsive nanocomposites and methods of their use
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
MX2013009456A (es) Compuestos de azufre aromaticos sustituidos y metodos para su uso.
WO2012004416A3 (en) Treatment of a disease associated with retinal degenerative disorder
LT2699545T (lt) Nauji amino-pirolino dariniai ir jų naudojimas metabolinio sindromo prevencijai ir (arba) gydymui
HK1193031A (en) Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
CL2015000348A1 (es) Uso de (s)-2-(3-aminopropil)-5-(2,5-difluorofenil)-n-metoxi-n-metil-2-fenil-1,3,4-tiadiazol-3(2h)-carboxamida (arry-520) para el tratamiento de cancer en un paciente que tiene un [aag] bajo.
HK1193342A (en) Pharmaceutical combination for use in the treatment of diabetes type 2
ZA201205434B (en) Coffins, sarcophagi, cinerary urns and the like

Legal Events

Date Code Title Description
FG Grant or registration